

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.,

Petitioner,

v.

LEPU BIOPHARMA CO., LTD.,

Patent Owner.

Case No. IPR2025-00685

U.S. Patent No. 10,792,370

**PATENT OWNER'S OBJECTION TO
PETITIONER'S DEMONSTRATIVES**

Patent Owner's Objection to Petitioner's Demonstratives

Patent Owner makes the following objection to Petitioner's Oral Hearing

Demonstratives.

Slide No.	Objection
21	Patent Owner objects to the new argument circled in red below for suggesting that Ground 2 includes “any anti-EGFR antibody,” an argument not previously presented in the record. Ground 2: Obviousness Over Leanna, Liu, and Wei Claims 1-23 are obvious over the combination of: Leanna (EX1006) + Liu (EX1007/1008) + Wei (EX1005) • Leanna provides the ADC architecture (vc-MMAE, any anti-EGFR antibody) • Liu provides BA03 with its superior properties • Wei provides additional confirmation of humanized cetuximab ADC viability Paper 1 at 65-67. DEMONSTRATIVE EXHIBIT – NOT EVIDENCE 21

Patent Owner's Objection to Petitioner's Demonstratives

Date: July 13, 2026

Respectfully,

SHEPPARD, MULLIN,
RICHTER & HAMPTON LLP

/Fangzhou Qiu/

Fangzhou Qiu (Reg. No. 82,810)

Attorneys for Patent Owner

Lepu Biopharma Co., Ltd.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on July 13, 2026, complete copies of the foregoing document were served via email to all parties to this proceeding at the addresses indicated:

Joe G. Chen, Ph.D. (joechen@foxrothschild.com)

Howard S. Suh (hsuh@foxrothschild.com)

Ryan N. Miller (rmiller@foxrothschild.com)

ipdocket@foxrothschild.com

Date: July 13, 2026

Respectfully,
SHEPPARD, MULLIN,
RICHTER & HAMPTON LLP

/Fangzhou Qiu/
Fangzhou Qiu (Reg. No. 82,810)
Attorneys for Patent Owner